Comparative analysis of postoperative outcomes and utilization trends for valve-in-valve transcatheter aortic valve implantation versus reoperative surgical aortic valve replacement

OBJECTIVE: To evaluate clinical outcomes, temporal trends, and age-related heterogeneity of valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) versus redo surgical aortic valve replacement (re-SAVR) in patients with failed aortic bioprosthetic valves. METHODS: Patients undergoing ViV-TAVI or re-SAVR between 2011 and 2021 were identified from the Nationwide Readmission Database (NRD). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline differences. Temporal trends in procedure utilization and patient age were assessed across calendar years. The primary outcome was all-cause mortality, including in-hospital, 30-day, and 6-month mortality. Secondary outcomes included in-hospital complications, all-cause readmission, and days alive and out of hospital (DAOH). Age-stratified and interaction analyses were performed. RESULTS: ViV-TAVI utilization increased significantly over time (p < 0.001), accompanied by a modest decline in patient age. Compared with re-SAVR, ViV-TAVI was associated with lower in-hospital mortality (OR 0.50, 95% CI 0.35-0.71; p < 0.001) and 30-day mortality (HR 0.60, 95% CI 0.43-0.83; p = 0.002), as well as lower risks of in-hospital stroke or transient ischemic attack, renal failure, and major bleeding (all p < 0.001). However, ViV-TAVI was associated with higher 30-day (HR 1.23, 95% CI 1.02-1.48; p = 0.031) and 6-month readmission (HR 1.25, 95% CI 1.07-1.46; p = 0.006). ViV-TAVI was also associated with higher DAOH at 30 days and 6 months (both p < 0.001). Interaction analyses suggested age-related heterogeneity for selected outcomes. CONCLUSIONS: ViV-TAVI use increased substantially and was associated with lower short-term mortality and fewer in-hospital complications, but higher readmission risk. Improved DAOH and potential age-related heterogeneity warrant further evaluation.

Authors

Institutions

Publication Details

Journal
Journal of Cardiothoracic Surgery
Published
2026-06-26
DOI
https://doi.org/10.1186/s13019-026-04370-9
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative analysis of postoperative outcomes and utilization trends for valve-in-valve transcatheter aortic valve implantation versus reoperative surgical aortic valve replacement

Cunhua Su, Jifang Zhou, Liming Zhao, Fan Yang et al.
Journal of Cardiothoracic Surgery
Cardiac Valve Diseases and Treatments
article

Comparative analysis of postoperative outcomes and utilization trends for valve-in-valve transcatheter aortic valve implantation versus reoperative surgical aortic valve replacement

Cunhua Su, Jifang Zhou, Liming Zhao, Fan Yang, Xiaodi Wang
article en

Abstract

OBJECTIVE: To evaluate clinical outcomes, temporal trends, and age-related heterogeneity of valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) versus redo surgical aortic valve replacement (re-SAVR) in patients with failed aortic bioprosthetic valves. METHODS: Patients undergoing ViV-TAVI or re-SAVR between 2011 and 2021 were identified from the Nationwide Readmission Database (NRD). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline differences. Temporal trends in procedure utilization and patient age were assessed across calendar years. The primary outcome was all-cause mortality, including in-hospital, 30-day, and 6-month mortality. Secondary outcomes included in-hospital complications, all-cause readmission, and days alive and out of hospital (DAOH). Age-stratified and interaction analyses were performed. RESULTS: ViV-TAVI utilization increased significantly over time (p < 0.001), accompanied by a modest decline in patient age. Compared with re-SAVR, ViV-TAVI was associated with lower in-hospital mortality (OR 0.50, 95% CI 0.35-0.71; p < 0.001) and 30-day mortality (HR 0.60, 95% CI 0.43-0.83; p = 0.002), as well as lower risks of in-hospital stroke or transient ischemic attack, renal failure, and major bleeding (all p < 0.001). However, ViV-TAVI was associated with higher 30-day (HR 1.23, 95% CI 1.02-1.48; p = 0.031) and 6-month readmission (HR 1.25, 95% CI 1.07-1.46; p = 0.006). ViV-TAVI was also associated with higher DAOH at 30 days and 6 months (both p < 0.001). Interaction analyses suggested age-related heterogeneity for selected outcomes. CONCLUSIONS: ViV-TAVI use increased substantially and was associated with lower short-term mortality and fewer in-hospital complications, but higher readmission risk. Improved DAOH and potential age-related heterogeneity warrant further evaluation.

Journal of Cardiothoracic Surgery
China Pharmaceutical University (CN), Nanjing Medical University (CN)
Good health and well-being
Openalex Percentile: Top 7%
Cardiac Valve Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.